BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 20, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 4/17 cls
Actelion Ltd. (SIX:ATLN) Jefferies Peter Welford Price target Hold -3% CHF48.92
Welford lowered his target to CHF50 from CHF72 assuming a price-to-earnings ratio in line with large-cap U.S. biopharmas. He remains cautious ahead of Phase III data, which he expects before year end, for Tracleer bosentan to treat idiopathic pulmonary fibrosis (IPF), clazosentan to prevent the occurrence of cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), and almorexant to treat primary insomnia.
Alkermes Inc. (NASDAQ:ALKS) BMO Capital Markets Robert Hazlett Upgrade Market perform (from underperform) -5% $8.10
Hazlett upgraded because he thinks the "issues and doubts" related to exenatide once weekly and Vivitrol naltrexone appear to be priced into Alkermes' shares. Exenatide once weekly is a long-acting GLP-1 agonist that uses Medisorb drug delivery technology from Alkermes and is being developed by Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) and Eli Lilly and Co. (NYSE:LLY). Hazlett expects Amylin and Lilly to submit an NDA by mid-year, with...

Read the full 1047 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >